The bill establishes a new grant program in West Virginia aimed at funding drug development trials for ibogaine, a substance being explored for its potential in treating opioid use disorder and other mental health conditions. The Secretary of Health is tasked with administering this program, which includes preparing a notice of funding opportunity, setting application requirements, and forming a selection committee composed of subject matter experts, philanthropic partners, and legislative designees. Eligible applicants must demonstrate their capacity to conduct the trials, submit a detailed plan for the drug development process, and ensure access to treatment for uninsured individuals, among other requirements.

Once an applicant is selected, they must submit an investigational new drug application to the U.S. Food and Drug Administration (FDA) and seek a breakthrough therapy designation for ibogaine. The bill outlines the establishment of drug development trial sites equipped for cardiac intensive care and mandates the selection of an institutional review board to oversee the trials. Funding for the program will come from state appropriations and donations, with selected applicants required to match the grant amount they receive. This initiative aims to facilitate the approval and development of ibogaine as a viable treatment option.

Statutes affected:
Introduced Version: 16-67-1, 16-67-2, 16-67-3, 16-67-4, 16-67-5, 16-67-6, 16-67-7
Engrossed Version: 16-67-1, 16-67-2, 16-67-3, 16-67-4, 16-67-5, 16-67-6, 16-67-7
Enrolled Version: 16-67-1, 16-67-2, 16-67-3, 16-67-4, 16-67-5, 16-67-6, 16-67-7